Mutations of Osteogenesis Imperfecta: Comparison
View Latest Version
Please note this is a comparison between Version 4 by Amina Yu and Version 3 by Dina Nadyrshina.

Osteogenesis Imperfecta (OI, Q78.0 according to ICD-10) is a rare genetic metabolic disease of the bone system with an autosomal dominant or a recessive type of inheritance. There are also X-linked forms and sporadic cases of this disease. The frequency of the disease in general varies from 1:15,000 to 1:20,000.

  • next-generation sequencing (NGS)
  • I type of collagen
  • metabolic bone disease

1. ВведениеIntroduction

The disease is characterized by bone fragility, skeletal deformity, short stature, blue sclera, progressive hearing loss and dentin anomaly. According to the modern classification, the disease is divided into 5 types [[1][2]. 2Osteogenesis ,imperfecta 3 ]. (OI) is a clinically and genetically heterogeneous hereditary connective-tissue disorder caused by the structural and quantitative changes in collagen, as well as disorders associated with its posttranslational modification, folding and intracellular transport. To date, the scientists have identified 21 genes that are responsible for the development of OI. Most patients with OI (80-90%) have autosomal dominant inheritance caused by mutations in the COL1A1 or COL1A2 genes encoding alpha-1 and alpha-2 chains of type I collagen [ 4 ][3].  Later, another gene was identified - IFITM5, mutations in which are responsible for the autosomal dominant type V of OI[4] [ 5 ]. Mutations in this gene occur in 4-5% of patients. Less than 10% patients with OI have recessive forms of inheritance caused by mutations in genes encoding proteins that are involved in the synthesis, transport, and post-translational modifications of collagen, or factors associated with differentiation and mineralization of bone cells (CRTAP,CRTAP, PPIB, BMP1, CCDC134, CREB3L1, FAM46A, FKBP10, P3H1, P4HB, PLOD2, PLS3, SEC24D, SERPINF1, SERPINH1, SP7, SPARC, TMEM38B)[5][2][6] PPIB, BMP1, CCDC134, CREB3L1, FAM46A, FKBP10, P3H1, P4HB, PLOD2, PLS3, SEC24D, SERPINF1, SERPINH1, SP7, SPARC, TMEM38B) [ 1, 3 , 6 ].

2. Mutations of the COL1A1 Gene

To date, it we know as known that more than 1000 structural changes in the COL1A1 gene. Structural mutations in this gene account for about 45% and the remaining number of mutations are accounted for by other variants (nonsense mutations, reading frame shift mutations, splicing site mutations, deletions of the entire gene). According to literaturehe data, the percent of new pathogenic mutations in two type I collagen genes (COL1A1/COL1A2) in Ukrainians with OI was 42.85%, in Chinese - 40.98%, in Swedes - 31.53% [ 4 , 12 , 19 ][3][7][8].  In the Chinese population, structural changes account for 54%, and haploinsufficiency mutations account for 46% [12], [7] in the Ukrainian population the ratio is exactly 49% / 51%[8] [ 19 ], which differs from ourthe results. In population from Republic of Baskortostan structural mutations account for 41%, and haploinsufficiency mutations-59%.

The studies of the thhree-spiral peptide have shown that a simple replacement of glycine in the medium (Gly-Pro-Hyp) strongly destabilizes the chain and affects the clinical severity of Osteogenesis Imperfecta. WeIt was also determined that the degree of destabilization of the peptide depends on that which amino acid replaces glycine (Gly). The order of stability loss from the smallest to the largest is as follows: Ala ≤ Ser <Cys <Arg <val <Glu ≤ Asp [ 27 , 28 ][9][10]. Substitutions of glycine with alanine and serine have the least effect on the conformation and stability of the peptide and lead to a lighter course of the disease [ 28 ][10]. Furthermore, the degree of destabilization depends on the location of the mutation site [ 29 ][11].

In lethal types of OI glycine substitutions for Val, Asp, Glu and Arg are observed more often. On the contrary, glycine substitutions for serine and cysteine are rare in patients with fatal cases of OI [ 5 , 30 , 31 ][4][12][13].

According to the  literature data, Gly residues are most often replaced by Ser or Cys [ 28 ][10].

Mutations c.358C>T, c.658C>T, c.1243C>T, c.2869C>T, c. 3076C>T, c.858+1G>A, c.1354-12G>A, c.3208-1G>C were detected in patients with type I of OI. Patients from other populations had similar clinical manifestations to patients from our study. Mutations c.1081C>T, c.2461G>A and c.2569G>T found in COL1A1 gene lead to severe clinical symptoms in ourthe patients with the type III of OI than in patients from literature   who had type I of OI [ 6 ][6].

Thus, the replacement of cytosine with thymine in the 1081 position of cDNA, leading to a stop codon in the proband from the Republic of Bashkortostan, led to severe clinical manifestations of the disease with type III of OI. He had multiple fractures, which led to deformities of the limbs and disability. The father with the same mutation had type I of OI. This change has been described 11 times, and ithe author was report a ed that a mild course of the disease with type I of OI [4,12,32,33,34,35][14][15][16][17][18][19]. The c.2461G>A mutation was registered in the database 31 times and described in patients with types I, II, III, and IV of OI [4,5,12,13,14,17,36,37,38,39,40,41][14][20][15][21][22][23][24][25][26][27][28][29]. KloenIt and co-authorwas described in detail a patient with this mutation who had multiple fractures with poor healing as a result of this progressive deformation of the lower and upper extremities and compression fractures of the spine. The patient could not move independently [40][28]. The patient also has multiple fractures and deformities of the limbs, which correlates with type III of OI.
The c.2569G>T mutation in the COL1A1 gene was described 8 times [5,42][20][30]. The phenotypes of patients also differed (II, III, IV types of OI). In the patient, this change led to type III of OI. The patient had multiple fractures, short stature, and deformities of the bone system.

3. Mutations of the COL1A2 Gene

There are about 600 mutations described in the COL1A2 gene. According to the international database on osteogenesis imperfecta, the vast majority of mutations in the COL1A2 gene are missense mutations, which account for approximately 74% [6][31].
It is noted that the most frequent structural defects of type I collagen causing osteogenesis imperfecta are glycine substitutions in the spiral domain. Glycine substitutions delay helical folding, increasing the access time for enzyme modification. Thus, in sample of OI patients, the most frequent missense mutations were glycine substitutions, which accounted for 73% of all structural changes identified in collagen genes.
Mutations in different type I collagen chains differ in their phenotypic effect. In the α1 chain of collagen type I, substitutions with charged or branched side chains disrupt the stability of the spiral and are predominantly lethal. Substitutions in the two main ligand-binding regions near the carboxyl end of the α1 chain have exceptionally lethal outcomes, indicating important interactions between the collagen monomer and non-collagen matrix proteins. In the α2 chain of type I collagen, substitutions are mostly non-lethal; however, eight lethal clusters along the chain align with proteoglycan binding sites on collagen fibrils. Finally, less than 5% of the mutations causing classical osteogenesis imperfecta occur in the procollagen C-propeptide, disrupting chain association or folding [43][32].
The c.874G>A mutation detected in the COL1A2 gene was published 6 times [4,20,41][14][6][29] and resulted in type I in 5 patients from Sweden and Germany [4,20][14][6] as well as a patient from Belarus. However, Duy described that this change led to type III of OI in a patient from Vietnam [41][29].
The c.2756G>A mutation of the COL1A2 gene was previously published in a patient with intrauterine fractures and various anomalies with type II of OI [44][33]. The patient had short stature, blue sclera, and multiple fractures, which led to disability of the patient and progressive deformities of the lower extremities with type III of OI.
The c.3034G>A mutation has been published 26 times in the database on OI [4,5,38,39,41,43,45,46,47][14][20][26][27][29][32][34][35][36]. Patients with this change had III and IV types of OI. According to clinical signs, ourthe patient was classified as type III of OI with blue sclera and multiple deforming fractures.
According to literaturehe data, haploinsufficiency mutations in COL1A1/COL1A2 genes resulting from splicing site mutations, meaningless mutations, deletions, or insertions usually create a premature termination codon. These aberrant RNAs are usually decomposed by nonsense-mediated mRNA decay (NMD). With normal type I collagen α chains produced by the wild-type allele, haploinsufficiency usually leads to a moderate OI phenotype [5][20]. On the other hand, the dominant negative effects are the result of missense mutations or mutations of the premature terminating codon, which avoid nonsense-mediated mRNA decay. Binding of the mutated α chain with normal α chains produced by the wild-type allele leads to an abnormal type of collagen I. Classically known OI mutations with a dominant negative effect represent the substitution of an amino acid for one of the mandatory glycine residues. TheyIt arewas found that in every third position in the COL1A1 chain and other mutations, such as defects in the passage of exons or deletions in the reading frame. Most cases of OI with dominant negative effects are usually more serious than cases of haploinsufficiency [48][37].
It hopes that the mutations in patients with OI and the clinical characteristics that has been described will contribute to the understanding of genotypic–phenotypic correlations.

4. Mutations in the P3H1 Gene

The phenotype of ourthe patient is similar to the patients described by Baldridge et al. (2008), who noted that mutations in this gene lead to different clinical characteristics compared to patients with mutations in type I collagen genes [49][38]. Patients are characterized by white sclera, round face, and deformities of the lower extremities. As the researchers note, zero mutations in the P3H1 gene cause type III of OI and are severe or lethal and lead to excessive modification of the entire spiral region of collagen. The P3H1 enzyme itself causes 3-hydroxylation of α1(I) Pro986 in type I collagen as part of a complex of three proteins (P3H1, CRTAP, and CypB) in a ratio of 1:1:1. P3H1 is a catalytically active component, whereas CRTAP is an auxiliary protein without a catalytic domain. Prolyl-3-hydroxylation is one of several modifications of pro-chains that contribute to the proper stacking, stability, and secretion of procollagen. Prolyl-4-hydroxylation is important for the thermal stability of the triple helix, while lysine hydroxylation and hydroxylysine glycosylation contribute to the extracellular stability of cross-links between molecules [50][39]. Zero mutations of P3H1 actually cancel the 3-hydroxylation of type I collagen. The absence of hydroxylation of α1(I) Pro986 and/or the direct chaperone effect of P3H1 leads to a delay in the folding of the collagen spiral [51][40]. Patients with mutations in this gene have been described in African Americans, Africans, Pakistanis, and Arabs. The researchers note that mutations in this gene most often occurred in consanguineous patients. Pepin et al. 2013 described founder-effect mutations in the African population [49,51,52][38][40][41]. Zero mutations in P3H1 or CRTAP lead to the absence of both proteins in mutant cells because these proteins are mutually supportive in the complex and ultimately lead to similar clinical signs in patients with OI.

5. Mutation of the IFITM5 Gene

Type V of OI is unique among all types of osteogenesis imperfecta: most patients (approximately 95%) with type V have the same heterozygous mutation in IFITM5, a point mutation in 5′-UTR (c.-14C>T), which generates a new starting codon and adds five residues to the N–terminal end of the protein. Patients with this type have moderate bone dysplasia with a different combination of distinctive features, including ossification of the interosseous membrane of the forearm (76–100%) and dislocation of the radial head (36–88%) and its displacement (86%) [53][42]. More than half of patients with type V develop hyperplastic corns during fracture healing. The sclera hue varies, and the teeth remain normal. All patients with type V have a distinct mesh plate on bone histology [54,55, 56 , 57 , 58 ][43][44][45][46][47].
In conclusion, osteogenesis imperfecta is a clinically and genetically heterogeneous disease. The same mutation can lead to different clinical manifestations of the disease. Therefore, each study contributes to the understanding of genotype-phenotype correlations in osteogenesis imperfecta.

References

  1. Van Dijk, F.; Sillence, D. Osteogenesis imperfecta: Clinical diagnosis, nomenclature and severity assessment. Am. J. Med. Genet. Part A 2014, 164, 1470–1481. [Google Scholar] [CrossRef]
  2. Zaripova, A.R.; Khusainova, R.I. Modern classification and molecular-genetic aspects of osteogenesis imperfecta. Vavilov J. Genet. Breed. 2020, 24, 219–227. [Google Scholar] [CrossRef] [PubMed]
  3. Lindahl, K.; Åström, E.; Rubin, C.-J.; Grigelioniene, G.; Malmgren, B.; Ljunggren, Ö.; Kindmark, A. Genetic epidemiology, prevalence, and genotype—Phenotype correlations in the Swedish population with osteogenesis imperfecta. Eur. J. Hum. Genet. 2015, 23, 1042–1050. [Google Scholar] [CrossRef] [PubMed]
  4. Marini, J.C.; Forlino, A.; Cabral, W.A.; Barnes, A.; Antonio, J.D.S.; Milgrom, S.; Hyland, J.C.; Körkkö, J.; Prockop, D.J.; De Paepe, A.; et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: Regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum. Mutat. 2007, 28, 209–221. [Google Scholar] [CrossRef]
  5. Forlino, A.; Marini, J.C. Osteogenesis imperfecta. Lancet 2016, 387, 1657–1671. [Google Scholar] [CrossRef]
  6. Available online: https://oi.gene.le.ac.uk/ (accessed on 9 December 2021).
  7. Zhang, Z.-L.; Zhang, H.; Ke, Y.-H.; Yue, H.; Xiao, W.-J.; Yu, J.-B.; Gu, J.-M.; Hu, W.-W.; Wang, C.; He, J.-W.; et al. The identification of novel mutations in COL1A1, COL1A2, and LEPRE1 genes in Chinese patients with osteogenesis imperfecta. J. Bone Miner. Metab. 2012, 30, 69–77. [Google Scholar] [CrossRef]
  8. Zhytnik, L.; Maasalu, K.; Pashenko, A.; Khmyzov, S.; Reimann, E.; Prans, E.; Kõks, S.; Märtson, A. COL1A1/2 Pathogenic Variants and Phenotype Characteristics in Ukrainian Osteogenesis Imperfecta Patients. Front. Genet. 2019, 10, 722. [Google Scholar] [CrossRef] [PubMed]
  9. Beck, K.; Chan, V.C.; Shenoy, N.; Kirkpatrick, A.; Ramshaw, J.A.M.; Brodsky, B. Destabilization of osteogenesis imperfecta collagen-like model peptides correlates with the identity of the residue replacing glycine. Proc. Natl. Acad. Sci. USA 2000, 97, 4273–4278. [Google Scholar] [CrossRef] [PubMed]
  10. Bryan, M.A.; Cheng, H.; Brodsky, B. Sequence environment of mutation affects stability and folding in collagen model peptides of osteogenesis imperfecta. Biopolymer 2011, 96, 4–13. [Google Scholar] [CrossRef] [PubMed]
  11. Makareeva, E.; Mertz, E.L.; Kuznetsova, N.V.; Sutter, M.B.; DeRidder, A.M.; Cabral, W.A.; Barnes, A.; McBride, D.J.; Marini, J.C.; Leikin, S. Structural Heterogeneity of Type I Collagen Triple Helix and Its Role in Osteogenesis Imperfecta. J. Biol. Chem. 2008, 283, 4787–4798. [Google Scholar] [CrossRef]
  12. Persikov, A.V.; Pillitteri, R.J.; Amin, P.; Schwarze, U.; Byers, P.H.; Brodsky, B. Stability related bias in residues replacing glycines within the collagen triple helix (Gly-Xaa-Yaa) in inherited connective tissue disorders. Hum. Mutat. 2004, 24, 330–337. [Google Scholar] [CrossRef]
  13. Xiao, J.; Cheng, H.; Silva, T.; Baum, J.; Brodsky, B. Osteogenesis Imperfecta Missense Mutations in Collagen: Structural Consequences of a Glycine to Alanine Replacement at a Highly Charged Site. Biochemistry 2011, 50, 10771–10780. [Google Scholar] [CrossRef]
  14. Van Dijk, F.; Sillence, D. Osteogenesis imperfecta: Clinical diagnosis, nomenclature and severity assessment. Am. J. Med. Genet. Part A 2014, 164, 1470–1481.
  15. Zaripova, A.R.; Khusainova, R.I. Modern classification and molecular-genetic aspects of osteogenesis imperfecta. Vavilov J. Genet. Breed. 2020, 24, 219–227.
  16. Lindahl, K.; Åström, E.; Rubin, C.-J.; Grigelioniene, G.; Malmgren, B.; Ljunggren, Ö.; Kindmark, A. Genetic epidemiology, prevalence, and genotype—Phenotype correlations in the Swedish population with osteogenesis imperfecta. Eur. J. Hum. Genet. 2015, 23, 1042–1050.
  17. Zhang, Z.-L.; Zhang, H.; Ke, Y.-H.; Yue, H.; Xiao, W.-J.; Yu, J.-B.; Gu, J.-M.; Hu, W.-W.; Wang, C.; He, J.-W.; et al. The identification of novel mutations in COL1A1, COL1A2, and LEPRE1 genes in Chinese patients with osteogenesis imperfecta. J. Bone Miner. Metab. 2012, 30, 69–77.
  18. Körkkö, J.; Ala-Kokko, L.; De Paepe, A.; Nuytinck, L.; Earley, J.; Prockop, D.J. Analysis of the COL1A1 and COL1A2 Genes by PCR Amplification and Scanning by Conformation-Sensitive Gel Electrophoresis Identifies Only COL1A1 Mutations in 15 Patients with Osteogenesis Imperfecta Type I: Identification of Common Sequences of Null-Allele Mutations. Am. J. Hum. Genet. 1998, 62, 98–110.
  19. Benusiené, E.; Kucinskas, V. COL1A1 mutation analysis in Lithuanian patients with osteogenesis imperfecta. J. Appl. Genet. 2003, 44, 95–102.
  20. Roschger, P.; Fratzl-Zelman, N.; Misof, B.M.; Glorieux, F.H.; Klaushofer, K.; Rauch, F. Evidence that Abnormal High Bone Mineralization in Growing Children with Osteogenesis Imperfecta is not Associated with Specific Collagen Mutations. Calcif. Tissue Int. 2008, 82, 263–270.
  21. Van Dijk, F.; Cobben, J.; Kariminejad, A.; Maugeri, A.; Nikkels, P.; van Rijn, R.; Pals, G. Osteogenesis Imperfecta: A Review with Clinical Examples. Mol. Syndr. 2011, 2, 1–20.
  22. Marini, J.C.; Forlino, A.; Cabral, W.A.; Barnes, A.; Antonio, J.D.S.; Milgrom, S.; Hyland, J.C.; Körkkö, J.; Prockop, D.J.; De Paepe, A.; et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: Regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum. Mutat. 2007, 28, 209–221.
  23. Venturi, G.; Tedeschi, E.; Mottes, M.; Valli, M.; Camilot, M.; Viglio, S.; Antoniazzi, F.; Tatò, L. Osteogenesis imperfecta: Clinical, biochemical and molecular findings. Clin. Genet. 2006, 70, 131–139.
  24. Lin, H.-Y.; Chuang, C.-K.; Su, Y.-N.; Chen, M.-R.; Chiu, H.-C.; Niu, D.-M.; Lin, S.-P. Genotype and phenotype analysis of Taiwanese patients with osteogenesis imperfecta. Orphanet J. Rare Dis. 2015, 10, 152.
  25. Fuccio, A.; Iorio, M.; Amato, F.; Elce, A.; Ingino, R.; Filocamo, M.; Castaldo, G.; Salvatore, F.; Tomaiuolo, R. A Novel DHPLC-Based Procedure for the Analysis of COL1A1 and COL1A2 Mutations in Osteogenesis Imperfecta. J. Mol. Diagn. 2011, 13, 648–656.
  26. Lund, A.M.; Skovby, F.; Schwartz, M. Serine for glycine substitutions in the C-terminal third of the α 1(I) chain of collagen I in five patients with nonlethal osteogenesis imperfecta. Hum. Mutat. 1997, 9, 378–382.
  27. Wang, Z.; Xu, D.-L.; Hu, J.-Y.; Liao, Y.-H.; Yang, Z.; Liang, Q.; Wang, L.-T. Gene mutation analysis of a Chinese family with osteogenesis imperfecta. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2006, 23, 192–194.
  28. Lee, K.-S.; Song, H.-R.; Cho, T.-J.; Kim, H.J.; Lee, T.-M.; Jin, H.-S.; Park, H.-Y.; Kang, S.; Jung, S.-C.; Koo, S.K. Mutational spectrum of type I collagen genes in Korean patients with osteogenesis imperfecta. Hum. Mutat. 2006, 27, 599.
  29. Nawawi, N.M.; Selveindran, N.M.; Rasat, R.; Chow, Y.P.; Latiff, Z.A.; Zakaria, S.Z.S.; Jamal, R.; Murad, N.A.A.; Aziz, B.B.A. Genotype-phenotype correlation among Malaysian patients with osteogenesis imperfecta. Clin. Chim. Acta 2018, 484, 141–147.
  30. Kloen, P.; Donders, J.C.; Eekhoff, E.M.W.; Hamdy, R.C. Pauwels Osteotomy for Femoral Neck Nonunion in Two Adult Siblings with Osteogenesis Imperfecta. Hip Pelvis 2018, 30, 53–59.
  31. Duy, B.H.; Zhytnik, L.; Maasalu, K.; Kändla, I.; Prans, E.; Reimann, E.; Märtson, A.; Kõks, S. Mutation analysis of the COL1A1 and COL1A2 genes in Vietnamese patients with osteogenesis imperfecta. Hum. Genom. 2016, 10, 27.
  32. Wang, Y.; Cui, Y.; Zhou, X.; Han, J. Development of a High-Throughput Resequencing Array for the Detection of Pathogenic Mutations in Osteogenesis Imperfecta. PLoS ONE 2015, 10, e0119553.
  33. Forlino, A.; D’Amato, E.; Valli, M.; Camera, G.; Hopkins, E.; Marini, J.C.; Cetta, G.; Coviello, D. Phenotypic Comparison of an Osteogenesis Imperfecta Type IV Proband with a de Novoα2(I) Gly922 → Ser Substitution in Type I Collagen and an Unrelated Patient with an Identical Mutation. Biochem. Mol. Med. 1997, 62, 26–35.
  34. Rolvien, T.; Stürznickel, J.; Schmidt, F.N.; Butscheidt, S.; Schmidt, T.; Busse, B.; Mundlos, S.; Schinke, T.; Kornak, U.; Amling, M.; et al. Comparison of Bone Microarchitecture Between Adult Osteogenesis Imperfecta and Early-Onset Osteoporosis. Calcif. Tissue Int. 2018, 103, 512–521.
  35. Barkova, E.; Mohan, U.; Chitayat, D.; Keating, S.; Toi, A.; Frank, J.; Frank, R.; Tomlinson, G.; Glanc, P. Fetal skeletal dysplasias in a tertiary care center: Radiology, pathology, and molecular analysis of 112 cases. Clin. Genet. 2014, 87, 330–337.
  36. Marini, J.C.; Lewis, M.B.; Wang, Q.; Chen, K.J.; Orrison, B.M. Serine for glycine substitutions in type I collagen in two cases of type IV osteogenesis imperfecta (OI). Additional evidence for a regional model of OI pathophysiology. J. Biol. Chem. 1993, 268, 2667–2673.
  37. Sztrolovics, R.; Glorieux, F.; Van Der Rest, M.; Roughley, P. Identification of type I collagen gene (COL1A2) mutations in nonlethal osteogenesis imperfecta. Hum. Mol. Genet. 1993, 2, 1319–1321.
  38. Stephen, J.; Girisha, K.M.; Dalal, A.; Shukla, A.; Shah, H.; Srivastava, P.; Kornak, U.; Phadke, S.R. Mutations in patients with osteogenesis imperfecta from consanguineous Indian families. Eur. J. Med. Genet. 2015, 58, 21–27.
  39. Ben Amor, I.M.; Roughley, P.; Glorieux, F.H.; Rauch, F. Skeletal clinical characteristics of osteogenesis imperfecta caused by haploinsufficiency mutations in COL1A1. J. Bone Miner. Res. 2013, 28, 2001–2007.
  40. Baldridge, D.; Schwarze, U.; Morello, R.; Lennington, J.; Bertin, T.K.; Pace, J.M.; Pepin, M.G.; Weis, M.; Eyre, D.R.; Walsh, J.; et al. CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta. Hum. Mutat. 2008, 29, 1435–1442.
  41. Myllyharju, J. Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends Genet. 2004, 20, 33–43.
  42. Cabral, W.A.; Chang, W.; Barnes, A.M.; Weis, M.; Scott, M.A.; Leikin, S.; Makareeva, E.; Kuznetsova, N.V.; Rosenbaum, K.N.; Tifft, C.J.; et al. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat. Genet. 2007, 39, 359–365.
  43. Pepin, M.G.; Schwarze, U.; Singh, V.; Romana, M.; Jones-LeCointe, A.; Byers, P.H. Allelic background of LEPRE1 mutations that cause recessive forms of osteogenesis imperfecta in different populations. Mol. Genet. Genom. Med. 2013, 1, 194–205.
  44. Cho, T.-J.; Lee, K.-E.; Lee, S.-K.; Song, S.J.; Kim, K.J.; Jeon, D.; Lee, G.; Kim, H.-N.; Lee, H.R.; Eom, H.-H.; et al. A Single Recurrent Mutation in the 5′-UTR of IFITM5 Causes Osteogenesis Imperfecta Type V. Am. J. Hum. Genet. 2012, 91, 343–348. [Google Scholar] [CrossRef]
  45. Grover, M.; Campeau, P.M.; Lietman, C.D.; Lu, J.T.; Gibbs, R.A.; Schlesinger, A.E.; Lee, B.H. Osteogenesis imperfecta without features of type V caused by a mutation in the IFITM5 gene. J. Bone Miner. Res. 2013, 28, 2333–2337. [Google Scholar] [CrossRef] [PubMed]
  46. Takagi, M.; Sato, S.; Hara, K.; Tani, C.; Miyazaki, O.; Nishimura, G.; Hasegawa, T. A recurrent mutation in the 5′-UTR of IFITM5 causes osteogenesis imperfecta type V. Am. J. Med. Genet. Part A 2013, 161, 1980–1982. [Google Scholar] [CrossRef] [PubMed]
  47. Shapiro, J.R.; Lietman, C.; Grover, M.; Lu, J.T.; Nagamani, S.C.; Dawson, B.C.; Baldridge, D.M.; Bainbridge, M.N.; Cohn, D.H.; Blazo, M.; et al. Phenotypic Variability of Osteogenesis Imperfecta Type V Caused by an IFITM 5 Mutation. J. Bone Miner. Res. 2013, 28, 1523–1530. [Google Scholar] [CrossRef] [PubMed]
  48. Persikov, A.V.; Pillitteri, R.J.; Amin, P.; Schwarze, U.; Byers, P.H.; Brodsky, B. Stability related bias in residues replacing glycines within the collagen triple helix (Gly-Xaa-Yaa) in inherited connective tissue disorders. Hum. Mutat. 2004, 24, 330–337. [Google Scholar] [CrossRef]
  49. Xiao, J.; Cheng, H.; Silva, T.; Baum, J.; Brodsky, B. Osteogenesis Imperfecta Missense Mutations in Collagen: Structural Consequences of a Glycine to Alanine Replacement at a Highly Charged Site. Biochemistry 2011, 50, 10771–10780. [Google Scholar] [CrossRef]
  50. Cho, T.-J.; Lee, K.-E.; Lee, S.-K.; Song, S.J.; Kim, K.J.; Jeon, D.; Lee, G.; Kim, H.-N.; Lee, H.R.; Eom, H.-H.; et al. A Single Recurrent Mutation in the 5′-UTR of IFITM5 Causes Osteogenesis Imperfecta Type V. Am. J. Hum. Genet. 2012, 91, 343–348. [Google Scholar] [CrossRef]
  51. Grover, M.; Campeau, P.M.; Lietman, C.D.; Lu, J.T.; Gibbs, R.A.; Schlesinger, A.E.; Lee, B.H. Osteogenesis imperfecta without features of type V caused by a mutation in the IFITM5 gene. J. Bone Miner. Res. 2013, 28, 2333–2337. [Google Scholar] [CrossRef] [PubMed]
  52. Takagi, M.; Sato, S.; Hara, K.; Tani, C.; Miyazaki, O.; Nishimura, G.; Hasegawa, T. A recurrent mutation in the 5′-UTR of IFITM5 causes osteogenesis imperfecta type V. Am. J. Med. Genet. Part A 2013, 161, 1980–1982. [Google Scholar] [CrossRef] [PubMed]
  53. Shapiro, J.R.; Lietman, C.; Grover, M.; Lu, J.T.; Nagamani, S.C.; Dawson, B.C.; Baldridge, D.M.; Bainbridge, M.N.; Cohn, D.H.; Blazo, M.; et al. Phenotypic Variability of Osteogenesis Imperfecta Type V Caused by an IFITM 5 Mutation. J. Bone Miner. Res. 2013, 28, 1523–1530. [Google Scholar] [CrossRef] [PubMed]
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback